Don't miss our weekly PhD newsletter | Sign up now Don't miss our weekly PhD newsletter | Sign up now

  *EASTBIO*Engineering sulfatases for biomedical applications


   School of Biology

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
  Dr T Gloster, Dr G Florence  No more applications being accepted  Competition Funded PhD Project (European/UK Students Only)

About the Project

BBSRC Theme: Industrial Biotechnology and Bioenergy

The project involves investigation of a human enzyme responsible for desulfation of heparan sulfate and heparin. The enzyme, (N-acetyl) glucosamine 6-sulfatase (G6S), is not particularly well characterized at the molecular level, but the Gloster group has recently obtained the structure of G6S using X-ray crystallography1. Gaining further insights into G6S activity is important for industrial biotechnology and biomedical applications.

Heparin, which is obtained from pig tissue, has been used as an anti-coagulant for a century. However, a contamination scare in 2008, which caused fatalities worldwide, has amplified the need for homogenous synthetic heparins. Given the difficulties often associated with chemical synthesis of large polysaccharides, enzymatic approaches are much more tractable. Ultra low molecular weight heparins (ULMWHs) have been demonstrated to work effectively as anti-coagulants. However, ULMWHs have one drawback as they can’t be neutralized by protamine sulfate, meaning there is no antidote if a patient is given an overdose of anti-coagulant. Others2 have shown that G6S desulfates ULMWHs, leading to molecules that are unable to bind to anti-thrombin III and are thus devoid of their anti-coagulation effect. Treatment with G6S could, therefore, be effective in the case of an overdose of anti-coagulant. However, given its lysosomal origin, G6S does not work effectively at physiological pH.

The aim of this project is to develop a robust assay to measure G6S activity, using novel synthetic substrates that will be synthesized in collaboration with chemists. This, in addition to the structural information already obtained, will be used as the basis for engineering G6S, using rational site directed mutagenesis, in order to obtain an enzyme that will work at higher pH. Such an engineered enzyme could then be explored used therapeutically as an antidote to anti-coagulant overdose.

The project is highly multi-disciplinary and will provide a rich training ground for a PhD student. This will include exposure to synthetic chemistry, molecular biology, protein biochemistry, enzymology, structural biology and cell biology.



Funding Notes

This project is eligible for the EASTBIO Doctoral Training Partnership: http://www.eastscotbiodtp.ac.uk/

This opportunity is only open to UK nationals (or EU students who have been resident in the UK for 3+ years immediately prior to the programme start date) due to restrictions imposed by the funding body.

Apply by 5.00 pm on 7 May 2018 following the instructions on how to apply at: http://www.eastscotbiodtp.ac.uk/how-apply-0

Informal inquiries to the primary supervisor are very strongly encouraged.


References

1. Unpublished
2. X Zhou, L Li, RJ Linhardt, J Liu. FEBS J, 2013, 280, 2523-32.

How good is research at University of St Andrews in Biological Sciences?


Research output data provided by the Research Excellence Framework (REF)

Click here to see the results for all UK universities